Atara Biotherapeutics Analyst Ratings
Atara Biotherapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/21/2023 | -6.04% | Citigroup | $2 → $1.4 | Maintains | Sell |
| 08/09/2023 | 1577.85% | EF Hutton | → $25 | Reiterates | Buy → Buy |
| 06/14/2023 | 1779.19% | HC Wainwright & Co. | $27 → $28 | Maintains | Buy |
| 05/09/2023 | 1242.28% | Canaccord Genuity | $50 → $20 | Maintains | Buy |
| 02/09/2023 | 1577.85% | EF Hutton | → $25 | Reiterates | → Buy |
| 02/09/2023 | 1712.08% | HC Wainwright & Co. | $29 → $27 | Maintains | Buy |
| 02/07/2023 | 1980.54% | Mizuho | → $31 | Reiterates | → Buy |
| 01/05/2023 | 1577.85% | EF Hutton | → $25 | Initiates Coverage On | → Buy |
| 08/16/2022 | 1980.54% | Mizuho | $39 → $31 | Maintains | Buy |
| 08/09/2022 | 101.34% | Goldman Sachs | $4 → $3 | Maintains | Sell |
| 07/20/2022 | 101.34% | Citigroup | → $3 | Downgrades | Neutral → Sell |
| 07/13/2022 | 571.14% | JP Morgan | → $10 | Downgrades | Overweight → Neutral |
| 07/13/2022 | 235.57% | Stifel | $16 → $5 | Downgrades | Buy → Hold |
| 05/24/2022 | 168.46% | Goldman Sachs | $5 → $4 | Maintains | Sell |
| 05/23/2022 | 1846.31% | HC Wainwright & Co. | $31 → $29 | Maintains | Buy |
| 05/10/2022 | 436.91% | Citigroup | $23 → $8 | Downgrades | Buy → Neutral |
| 03/28/2022 | 1376.51% | JP Morgan | $27 → $22 | Maintains | Overweight |
| 01/03/2022 | 1712.08% | JP Morgan | $26 → $27 | Maintains | Overweight |
| 05/13/2021 | 1846.31% | JP Morgan | $23 → $29 | Upgrades | Neutral → Overweight |
| 05/05/2021 | 1980.54% | HC Wainwright & Co. | $32 → $31 | Maintains | Buy |
| 12/08/2020 | 1980.54% | HC Wainwright & Co. | $28 → $31 | Maintains | Buy |
| 11/10/2020 | 1779.19% | HC Wainwright & Co. | $26 → $28 | Maintains | Buy |
| 09/15/2020 | 5134.9% | Canaccord Genuity | $70 → $78 | Maintains | Buy |
| 08/06/2020 | 1779.19% | Stifel | $30 → $28 | Maintains | Buy |
| 08/06/2020 | 1644.97% | HC Wainwright & Co. | $25 → $26 | Maintains | Buy |
| 06/30/2020 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 06/15/2020 | 1577.85% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 05/12/2020 | 1443.62% | JP Morgan | $22 → $23 | Maintains | Neutral |
| 04/23/2020 | — | Citigroup | Upgrades | Neutral → Buy | |
| 11/08/2019 | 1376.51% | JP Morgan | $43 → $22 | Downgrades | Overweight → Neutral |
| 09/27/2019 | 504.03% | Goldman Sachs | $14 → $9 | Downgrades | Neutral → Sell |
| 09/16/2019 | 906.71% | Jefferies | $32 → $15 | Downgrades | Buy → Hold |
| 06/04/2019 | — | Citigroup | Upgrades | Sell → Neutral | |
| 05/30/2019 | 1913.42% | Roth Capital | → $30 | Initiates Coverage On | → Buy |
| 05/23/2019 | 2651.68% | Stifel | → $41 | Initiates Coverage On | → Buy |
| 01/23/2019 | 4061.07% | Mizuho | → $62 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月21日 | -6.04% | 花旗集團 | $2→$1.4 | 維護 | 賣 |
| 08/09/2023 | 1577.85% | EF Hutton | →$25 | 重申 | 購買→購買 |
| 2023/06/14 | 1779.19% | HC Wainwright公司 | $27→$28 | 維護 | 買 |
| 05/09/2023 | 1242.28% | 卡納科特·格納奇 | $50→$20 | 維護 | 買 |
| 02/09/2023 | 1577.85% | EF Hutton | →$25 | 重申 | →購買 |
| 02/09/2023 | 1712.08% | HC Wainwright公司 | $29→$27 | 維護 | 買 |
| 02/07/2023 | 1980.54% | 瑞穗 | →$31 | 重申 | →購買 |
| 01/05/2023 | 1577.85% | EF Hutton | →$25 | 開始承保 | →購買 |
| 08/16/2022 | 1980.54% | 瑞穗 | $39→$31 | 維護 | 買 |
| 08/09/2022 | 101.34% | 高盛 | $4→$3 | 維護 | 賣 |
| 07/20/2022 | 101.34% | 花旗集團 | →$3 | 評級下調 | 中性→銷售 |
| 07/13/2022 | 571.14% | 摩根大通 | →$10 | 評級下調 | 超重→中性 |
| 07/13/2022 | 235.57% | Stifel | $16→$5 | 評級下調 | 購買→Hold |
| 2022年05月24日 | 168.46% | 高盛 | $5→$4 | 維護 | 賣 |
| 2022年05月23日 | 1846.31% | HC Wainwright公司 | $31→$29 | 維護 | 買 |
| 2022年05月10日 | 436.91% | 花旗集團 | $23→$8 | 評級下調 | 購買→中性 |
| 03/28/2022 | 1376.51% | 摩根大通 | $27→$22 | 維護 | 超重 |
| 01/03/2022 | 1712.08% | 摩根大通 | $26→$27 | 維護 | 超重 |
| 2021/05/13 | 1846.31% | 摩根大通 | $23→$29 | 升級 | 中性→超重 |
| 05/05/2021 | 1980.54% | HC Wainwright公司 | $32→$31 | 維護 | 買 |
| 12/08/2020 | 1980.54% | HC Wainwright公司 | $28→$31 | 維護 | 買 |
| 11/10/2020 | 1779.19% | HC Wainwright公司 | $26→$28 | 維護 | 買 |
| 2020/09/15 | 5134.9% | 卡納科特·格納奇 | $70→$78 | 維護 | 買 |
| 08/06/2020 | 1779.19% | Stifel | $30→$28 | 維護 | 買 |
| 08/06/2020 | 1644.97% | HC Wainwright公司 | $25→$26 | 維護 | 買 |
| 06/30/2020 | - | Evercore ISI集團 | 開始承保 | →跑贏大盤 | |
| 2020/06/15 | 1577.85% | HC Wainwright公司 | →$25 | 開始承保 | →購買 |
| 2020/05/12 | 1443.62% | 摩根大通 | $22→$23 | 維護 | 中性 |
| 04/23/2020 | - | 花旗集團 | 升級 | 中性→購買 | |
| 2019年8月11日 | 1376.51% | 摩根大通 | $43→$22 | 評級下調 | 超重→中性 |
| 2019年09月27日 | 504.03% | 高盛 | $14→$9 | 評級下調 | 中性→銷售 |
| 2019/09/16 | 906.71% | 傑富瑞 | $32→$15 | 評級下調 | 購買→Hold |
| 2019年04月06日 | - | 花旗集團 | 升級 | 賣出→中性 | |
| 2019年05月30日 | 1913.42% | 羅斯資本 | →$30 | 開始承保 | →購買 |
| 2019年05月23日 | 2651.68% | Stifel | →$41 | 開始承保 | →購買 |
| 2019年01月23日 | 4061.07% | 瑞穗 | →$62 | 開始承保 | →購買 |
What is the target price for Atara Biotherapeutics (ATRA)?
Atara BioTreateutics(ATRA)的目標價格是多少？
The latest price target for Atara Biotherapeutics (NASDAQ: ATRA) was reported by Citigroup on August 21, 2023. The analyst firm set a price target for $1.40 expecting ATRA to fall to within 12 months (a possible -6.04% downside). 8 analyst firms have reported ratings in the last year.
花旗集團於2023年8月21日報道了Atara BioTreatetics(納斯達克：ATRA)的最新目標價。這家分析公司將目標價定為1.40美元，預計ATRA將在12個月內下跌(可能下跌6.04%)。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Atara Biotherapeutics (ATRA)?
Atara BioTreateutics(ATRA)的最新分析師評級是什麼？
The latest analyst rating for Atara Biotherapeutics (NASDAQ: ATRA) was provided by Citigroup, and Atara Biotherapeutics maintained their sell rating.
Atara BioTreateutics(納斯達克：ATRA)的最新分析師評級由花旗集團提供，Atara BioTreateutics維持賣出評級。
When is the next analyst rating going to be posted or updated for Atara Biotherapeutics (ATRA)?
Atara BioTreateutics(ATRA)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atara Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atara Biotherapeutics was filed on August 21, 2023 so you should expect the next rating to be made available sometime around August 21, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Atara BioTreateutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Atara BioTreatetics的上一次評級是在2023年8月21日提交的，所以你應該預計下一次評級將在2024年8月21日左右的某個時候提供。
Is the Analyst Rating Atara Biotherapeutics (ATRA) correct?
分析師對Atara BioTreateutics(ATRA)的評級正確嗎？
While ratings are subjective and will change, the latest Atara Biotherapeutics (ATRA) rating was a maintained with a price target of $2.00 to $1.40. The current price Atara Biotherapeutics (ATRA) is trading at is $1.49, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Atara BioTreateutics(ATRA)評級保持不變，目標價在2.00美元至1.40美元之間。目前Atara BioTreateutics(ATRA)的交易價格為1.49美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。